Human T-lymphotropic virus 2
| Human T-lymphotropic virus 2 | |
|---|---|
| Specialty | Infectious diseases |
| Symptoms | Mild cognitive Impairment, Mycosis fungoides |
| Duration | Chronic, incurable |
| Causes | HTLV-2 |
| Risk factors | Unsafe sex, haemophiliacs |
| Diagnostic method | Blood test |
| Differential diagnosis | HIV/AIDS, Lymphoma, HTLV-1 |
| Prevention | Practicing safe-sex, use of clean needles, screening blood transfusions, Avoiding breastfeeding. |
| Medication | Antiretrovirals, chemotherapy |
| Prognosis | 95% present with no symptoms, generally good |
| Frequency | 15-20 million people worldwide |
| Human T-lymphotropic virus 2 | |
|---|---|
| Virus classification | |
| (unranked): | Virus |
| Realm: | Riboviria |
| Kingdom: | Pararnavirae |
| Phylum: | Artverviricota |
| Class: | Revtraviricetes |
| Order: | Ortervirales |
| Family: | Retroviridae |
| Genus: | Deltaretrovirus |
| Species: | Deltaretrovirus priTlym2 |
A virus closely related to HTLV-I, human T-lymphotropic virus 2 (HTLV-II) shares approximately 70% genomic homology (structural similarity) with HTLV-I. It was discovered by Robert Gallo and colleagues.
HTLV-2 is prevalent in Africa and among Indigenous peoples in Central and South America, as well as among drug users in Europe and North America. It can be passed down from mother to child through breast milk, and even genetically from either parent.
HTLV-II entry in target cells is mediated by the glucose transporter GLUT1.